Names | |
---|---|
IUPAC name
(4S,5aS,8S,8aR)-N-[(1S,2S)-2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-4-(2-methylpropyl)-3,4,5,5a,6,7,8,8a-octahydro-2H-oxepino[2,3-c]pyrrole-8-carboxamide
| |
Identifiers | |
3D model (
JSmol)
|
|
PubChem
CID
|
|
| |
| |
Properties | |
C22H39ClN2O6S | |
Molar mass | 495.07 g·mol−1 |
Related compounds | |
Related compounds
|
Cresomycin |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
Iboxamycin is a synthetic lincosamide or oxepanoprolinamide antibiotic. It binds to the bacterial ribosome in both Gram-negative and Gram-positive bacteria and it has been found to effective against bacteria which are resistant to other antibiotics that target the large ribosomal subunit. It was developed by combining an oxepano proline unit with the aminooctose residue of clindamycin. [1]
Iboxamycin has been found to be effective against ESKAPE bacteria, methicillin-resistant Staphylococcus aureus (MRSA), Enterococcus, Clostridium difficile, [1] and Listeria monocytogenes, [2] indicating an extended spectrum when compared to clindamycin. [1] Isotopic labeling of iboxamycin with tritium indicated that it binds 70 times more tightly to the ribosome than clindamycin. [3]
Iboxamycin can be administered orally and has been found to be safe when administered to mice. [1] It is a bacteriostatic antibiotic. [1]
Names | |
---|---|
IUPAC name
(4S,5aS,8S,8aR)-N-[(1S,2S)-2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-4-(2-methylpropyl)-3,4,5,5a,6,7,8,8a-octahydro-2H-oxepino[2,3-c]pyrrole-8-carboxamide
| |
Identifiers | |
3D model (
JSmol)
|
|
PubChem
CID
|
|
| |
| |
Properties | |
C22H39ClN2O6S | |
Molar mass | 495.07 g·mol−1 |
Related compounds | |
Related compounds
|
Cresomycin |
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
Iboxamycin is a synthetic lincosamide or oxepanoprolinamide antibiotic. It binds to the bacterial ribosome in both Gram-negative and Gram-positive bacteria and it has been found to effective against bacteria which are resistant to other antibiotics that target the large ribosomal subunit. It was developed by combining an oxepano proline unit with the aminooctose residue of clindamycin. [1]
Iboxamycin has been found to be effective against ESKAPE bacteria, methicillin-resistant Staphylococcus aureus (MRSA), Enterococcus, Clostridium difficile, [1] and Listeria monocytogenes, [2] indicating an extended spectrum when compared to clindamycin. [1] Isotopic labeling of iboxamycin with tritium indicated that it binds 70 times more tightly to the ribosome than clindamycin. [3]
Iboxamycin can be administered orally and has been found to be safe when administered to mice. [1] It is a bacteriostatic antibiotic. [1]